Evaluation of the utility of the lifetime mouse bioassay in the identification of cancer hazards for humans

Food and Chemical Toxicology

Volumn 60, Issue , 2013, Pages 550-562

  Osimitz, Thomas G ^a   Droege, Wiebke ^a   Boobis, Alan R ^b   Lake, Brian G ^c  

^a Science Strategies LLC   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Ames mutagenicity assay; Cancer bioassay; Genotoxicity; Human relevance; Mode of action; Non genotoxic carcinogens

Indexed keywords

4 TOLYLUREA; CAPTAN; CHEMICAL COMPOUND; O BENZYL 4 CHLOROPHENOL; PENTOSAN POLYSULFATE; UNCLASSIFIED DRUG;

ADENOMA; AMES TEST; ARTICLE; BIOASSAY; CANCER BIOASSAY; CANCER RISK; CANCER SCREENING; CARCINOGENICITY; CELL PROLIFERATION; CHEMICAL DATABASE; CHROMOSOME ABERRATION; CYTOTOXICITY; GENE LOCUS; GENETIC SUSCEPTIBILITY; GENOTOXICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DISEASE; LIVER CANCER; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAXIMUM TOLERATED DOSE; NEPHROTOXICITY; NONGENOTOXICITY; NONHUMAN; RENAL TUBULAR HYPERPLASIA; RENAL TUBULE ADENOMA; RISK ASSESSMENT; WEB BROWSER;

AMES MUTAGENICITY ASSAY; BCP; CANCER BIOASSAY; CAR; CARCINOGENIC POTENCY DATABASE; CONSTITUTIVE ANDROSTANE RECEPTOR; CPDB; DEOXYRIBONUCLEIC ACID; DNA; EAFUS; EU; EUROPEAN UNION; EVERYTHING ADDED TO FOOD IN THE UNITED STATES; FDA; GENOTOXICITY; HAZARDOUS SUBSTANCES DATA BANK; HSDB; HUMAN RELEVANCE; IARC; INTERNATIONAL AGENCY FOR RESEARCH ON CANCER; INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY; IPCS; MAXIMUM TOLERATED DOSE; MEDIAN TOXIC DOSE VALUE; MODE OF ACTION; MTD; NATIONAL CANCER INSTITUTE; NATIONAL TOXICOLOGY PROGRAM; NCI; NON-GENOTOXIC CARCINOGENS; NTP; O-BENZYL-P-CHLOROPHENOL; OECD; ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT; OSTP; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA; PPARΑ; QSAR; QUANTITATIVE STRUCTURE-ACTIVITY; REACH; REGISTRATION, EVALUATION, AUTHORISATION AND RESTRICTION OF CHEMICAL SUBSTANCES; TD50; TOXIC SUBSTANCES CONTROL ACT; TSCA; U.S. OFFICE OF SCIENCE AND TECHNOLOGY POLICY; UNITED STATES ENVIRONMENTAL PROTECTION AGENCY; UNITED STATES FOOD AND DRUG ADMINISTRATION; USEPA;

ANIMALS; BIOLOGICAL ASSAY; CARCINOGENICITY TESTS; CARCINOGENS; DATABASES, FACTUAL; DNA DAMAGE; DRUG EVALUATION, PRECLINICAL; HUMANS; INTERNET; MICE; NEOPLASMS; RATS;

EID: 84883504466     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.08.020     Document Type: Article

References (95)

1. 113th United States Congress, 2013a. Bill Summary & Status 113th Congress (2013 - 2014) S.696. Safe Chemicals Act of 2013, The Library of Congress. http://thomas.loc.gov (accessed 31.07.13).
2. 113th United States Congress, 2013b. Bill Summary & Status 113th Congress (2013 - 2014) H.R.1385. Safe Cosmetics and Personal Care Products Act of 2013. (accessed 31.07.13). http://thomas.loc.gov.
3. ACToR, 2011. (accessed 25.04.13). http://actor.epa.gov.
4. Alden C.L., Smith P.F., Piper C.E., Brej L. A critical appraisal of the value of the mouse cancer bioassay in safety assessment. Toxicol. Pathol. 1996, 24:722-725.
5. Ames B.N., Gold L.S. Paracelsus to parascience: the environmental cancer distraction. Mutat. Res. 2000, 447:3-13.
6. Ashby J. Alternatives to the 2-species bioassay for the identification of potential human carcinogens. Hum. Exp. Toxicol. 1996, 15:183-202.
7. Ashby J., Tennant R.W. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat. Res. - Rev. Gen. Toxicol. 1991, 257:229-306.
8. Bajpayee M., Pandey A.K., Parmar D., Dhawan A. Current status of short-term tests for evaluation of genotoxicity, mutagenicity, and carcinogenicity of environmental chemicals and NCEs. Toxicol. Mech. Methods 2005, 15:155-180.
9. Battershill J.M., Fielder R.J. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice. Hum. Exp. Toxicol. 1998, 17:193-205.
10. Becker F.F. Morphological classification of mouse liver tumors based on biological characteristics. Cancer Res. 1982, 42:3918-3923.
11. Billington R., Lewis R.W., Mehta J.M., Dewhurst I. The mouse carcinogenicity study is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides. Crit. Rev. Toxicol. 2010, 40:35-49.
12. Board of Scientific Counselors National Toxicology Program, 1984. Report of the NTP Ad Hoc Panel on Chemical Carcinogenesis Testing and Evaluation. (accessed 25.04.13). http://ntp.niehs.nih.gov/ntp/About_ntp/BSC/1984/August/NTPAdHocPanel1984_508.pdf.
13. Boobis A.R., Cohen S.M., Dellarco V., McGregor D., Meek M.E., Vickers C., Willcocks D., Farland W. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit. Rev. Toxicol. 2006, 36:781-792.
14. Bucher J.R., Portier C. Human carcinogenic risk evaluation, Part V: The national toxicology program vision for assessing the human carcinogenic hazard of chemicals. Toxicol. Sci. 2004, 82:363-366.
15. Bursch W., Chabicovsky M., Wastl U., Grasl-Kraupp B., Bukowska K., Taper H., Schulte-Hermann R. Apoptosis in stages of mouse hepatocarcinogenesis: failure to counterbalance cell proliferation and to account for strain differences in tumor susceptibility. Toxicol. Sci. 2005, 85:515-529.
16. Carmichael N.G., Enzmann H., Pate I., Waechter F. The significance of mouse liver tumor formation for carcinogenic risk assessment: results and conclusions from a survey of ten years of testing by the agrochemical industry. Environ. Health Perspect. 1997, 105:1196-1203.
17. Clayson D.B., Nera E.A., Lok E. The potential for the use of cell proliferation studies in carcinogen risk assessment. Regul. Toxicol. Pharmacol. 1989, 9:284-295.
18. Cohen S.M. Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay. Toxicol. Sci. 2004, 80:225-229.
19. Cohen S.M. An enhanced 13-week bioassay: an alternative to the 2-year bioassay to screen for human carcinogenesis. Exp. Toxicol. Pathol. 2010, 62:497-502.
20. Cohen S.M. Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: the two-year bioassay is no longer necessary. Toxicol. Pathol. 2010, 38:487-501.
21. Cohen S.M., Arnold L.L. Cell proliferation and carcinogenesis. Journal of Toxicologic Pathology 2008, 21:1-7.
22. Cohen S.M., Arnold L.L. Chemical carcinogenesis. Toxicol. Sci. 2011, 120(Suppl. 1). S76-92.
23. Cohen S.M., Ellwein L.B. Cell proliferation in carcinogenesis. Science 1990, 249:1007-1011.
24. Cohen S.M., Robinson D., MacDonald J. Alternative models for carcinogenicity testing. Toxicol. Sci. 2001, 64:14-19.
25. Counts J.L., Goodman J.I. Principles underlying dose selection for, and extrapolation from, the carcinogen bioassay: dose influences mechanism. Regul. Toxicol. Pharmacol. 1995, 21:418-421.
26. Dearfield K.L., Cimino M.C., McCarroll N.E., Mauer I., Valcovic L.R. Genotoxicity risk assessment: a proposed classification strategy. Mutat. Res. 2002, 521:121-135.
27. Diwan B.A., Rice J.M., Ohshima M., Ward J.M. Interstrain differences in susceptibility to liver carcinogenesis initiated by N-nitrosodiethylamine and its promotion by phenobarbital in C57BL/6NCr, C3H/HeNCrMTV- and DBA/2NCr mice. Carcinogenesis 1986, 7:215-220.
28. Dragani T.A. 10 years of mouse cancer modifier loci: human relevance. Cancer Res. 2003, 63:3011-3018.
29. Drinkwater N.R., Ginsler J.J. Genetic control of hepatocarcinogenesis in C57BL/6J and C3H/HeJ inbred mice. Carcinogenesis 1986, 7:1701-1707.
30. European Commission, 1967. General classification and labelling requirements for dangerous substances and preparations. Council Directive 67/548/EEC of 27 June 1967 on the Approximation of Laws, Regulations and Administrative Provisions Relating to the Classification, Packaging and Labelling of Dangerous Substances. European Commission, Annex VI. (accessed 25.04.13). http://europa.eu/legislation_summaries/consumers/product_labelling_and_packaging/l21276_en.htm.
31. European Commission, 2006. Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 Concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), Establishing a European Chemicals Agency, Amending Directive 1999/45/EC and Repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as Well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. (accessed 25.04.13). http://eur-lex.europa.eu/.
32. Evans J.G., Collins M.A., Lake B.G., Butler W.H. The histology and development of hepatic nodules and carcinoma in C3H/He and C57BL/6 mice following chronic phenobarbitone administration. Toxicol. Pathol. 1992, 20:585-594.
33. FDA, 2000. Toxicological Principles for the Safety Assessment of Food Ingredients Redbook 2000 (revised July 2007). (accessed 25.04.13). http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/IngredientsAdditivesGRASPackaging/ucm2006826.htm.
34. FDA, 2013. International Conference on Harmonisation; Proposed Change to Rodent Carcinogenicity Testing of Pharmaceuticals; Request for Comments. Publication Date: Monday, March 18, 2013. Docket No. FDA-2013-N-0222, pp. 16681-1668. <#!home (accessed 30.07.13). http://www.regulations.gov/.
35. FDA Advisory Committee Food and Drug Administration Advisory Committee on protocols for safety evaluation: panel on carcinogenesis report on cancer testing in the safety evaluation of food additives and pesticides. Toxicol. Appl. Pharmacol. 1971, 20:419-438.
36. Fleischman R.W., Baker J.R., Hagopian M., Wade G.G., Hayden D.W., Smith E.R., Weisburger J.H., Weisburger E.K. Carcinogenesis bioassay of acetamide, hexanamide, adipamide, urea and P-tolylurea in mice and rats. J. Environ. Pathol. Toxicol. 1980, 3:149-170.
37. Friedman G.D., Jiang S.F., Udaltsova N., Quesenberry C.P., Chan J., Habel L.A. Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity. Int. J. Cancer 2009, 125:2173-2178.
38. Gaylor D.W. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?. Regul. Toxicol. Pharmacol. 2005, 41:128-133.
39. Gold L.S., Manley N.B., Slone T.H., Ward J.M. Compendium of chemical carcinogens by target organ: results of chronic bioassays in rats, mice, hamsters, dogs, and monkeys. Toxicol. Pathol. 2001, 29:639-652.
40. Gold L.S., Slone T.H., Ames B.N. What do animal cancer tests tell us about human cancer risk? Overview of analyses of the carcinogenic potency database. Drug Metab. Rev. 1998, 30:359-404.
41. Golden R.J., Holm S.E., Robinson D.E., Julkunen P.H., Reese E.A. Chloroform mode of action: implications for cancer risk assessment. Regul. Toxicol. Pharmacol. 1997, 26:142-155.
42. Goldsworthy T.L., Fransson-Steen R. Quantitation of the cancer process in C57BL/6J, B6C3F1 and C3H/HeJ mice. Toxicol. Pathol. 2002, 30:97-105.
43. Gori G.B. Regulatory forum opinion piece: long-term animal bioassays: is the end near?. Toxicol. Pathol. 2013, 41:805-807.
44. Grasso P., Crampton R.F. The value of the mouse in carcinogenicity testing. Food Cosmet Toxicol 1972, 10:418-426.
45. Grasso P., Hinton R.H. Evidence for and possible mechanisms of non-genotoxic carcinogenesis in rodent liver. Mutat. Res. 1991, 248:271-290.
46. Hayes A.W., Dayan A.D., Hall W.C., Kodell R.L., Williams G.M., Waddell W.D., Slesinski R.S., Kruger C.L. A review of mammalian carcinogenicity study design and potential effects of alternate test procedures on the safety evaluation of food ingredients. Regul. Toxicol. Pharmacol. 2011, 60. S1-34.
47. Holsapple M.P., Pitot H.C., Cohen S.M., Boobis A.R., Klaunig J.E., Pastoor T., Dellarco V.L., Dragan Y.P. Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol. Sci. 2006, 89:51-56.
48. HSDB, 2011. (accessed 25.04.13). http://toxnet.nlm.nih.gov.
49. Huff J., Cirvello J., Haseman J., Bucher J. Chemicals associated with site-specific neoplasia in 1394 long-term carcinogenesis experiments in laboratory rodents. Environ. Health Perspect. 1991, 93:247-270.
50. IARC, 2001. Phenobarbital and its sodium salt (Group 2B). Summary of Data Reported and Evaluation. (accessed 25.04.13). http://www.inchem.org/documents/iarc/vol79/79-06.html.
51. IARC, 2013. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. (accessed 25.04.13). http://monographs.iarc.fr/ENG/Monographs/PDFs/index.php.
52. Kirkland D., Aardema M., Henderson L., Muller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat. Res. 2005, 584:1-256.
53. Kirkland D., Aardema M., Muller L., Makoto H. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumour profiles. Mutat. Res. 2006, 608:29-42.
54. Klaunig J.E., Babich M.A., Baetcke K.P., Cook J.C., Corton J.C., David R.M., DeLuca J.G., Lai D.Y., McKee R.H., Peters J.M., Roberts R.A., Fenner-Crisp P.A. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 2003, 33:655-780.
55. Lake B.G. Species differences in the hepatic effects of inducers of CYP2B and CYP4A subfamily forms: relationship to rodent liver tumour formation. Xenobiotica 2009, 39:582-596.
56. Lave L.B., Ennever F.K., Rosenkranz H.S., Omenn G.S. Information value of the rodent bioassay. Nature 1988, 336:631-633.
57. Liu Z., Kelly R., Fang H., Ding D., Tong W. Comparative analysis of predictive models for nongenotoxic hepatocarcinogenicity using both toxicogenomics and quantitative structure-activity relationships. Chem. Res. Toxicol. 2011, 24:1062-1070.
58. Lutz W.K. Dose-response relationships in chemical carcinogenesis: superposition of different mechanisms of action, resulting in linear-nonlinear curves, practical thresholds, J-shapes. Mutat. Res. 1998, 405:117-124.
59. Manenti G., Galvan A., Falvella F.S., Pascale R.M., Spada E., Milani S., Gonzalez Neira A., Feo F., Dragani T.A. Genetic control of resistance to hepatocarcinogenesis by the mouse Hpcr3 locus. Hepatology 2008, 48:617-623.
60. Manibusan M., Mitkus R., Shah P., Rowland J., May B., Akerman G., Baetke K., Dellarco V. Assessment of the rodent carcinogenicity testing requirements for pesticides, abstract 1495. Toxicologist 2009, 108:310.
61. Maronpot R.R., Boorman G.A. The contribution of the mouse in hazard identification studies. Toxicol. Pathol. 1996, 24:726-731.
62. Marsman D.S., Grumbein S.L., Haseman J.K., Hailey J.R. Chronic nephropathy and renal carcinogenicity of o-benzyl-p-chlorophenol in F344/N rats and B6C3F1 mice. Fundam. Appl. Toxicol. 1995, 27:252-262.
63. Meek M.E., Bucher J.R., Cohen S.M., Dellarco V., Hill R.N., Lehman-McKeeman L.D., Longfellow D.G., Pastoor T., Seed J., Patton D.E. A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 2003, 33:591-653.
64. Ministry of Agriculture, Forestry and Fisheries, 2006. The Proposed basic Guidelines on Carrying out of Animal Experimentation in Research Laboratories (Japanese). (accessed 23.04.13). http://www.maff.go.jp/www/press/2006/20060601press_2.htmlS.
65. Moloney J.B. The murine leukemias. Fed. Proc. 1962, 21:19-31.
66. Monro A. How useful are chronic (life-span) toxicology studies in rodents in identifying pharmaceuticals that pose a carcinogenic risk to humans?. Adverse Drug React. Toxicol. Rev. 1993, 12:5-34.
67. Newberne P.M. Choline deficiency associated with diethanolamine carcinogenicity. Toxicol. Sci. 2002, 67:1-3.
68. NTP, 1995. Technical Report Series No. 444 NIH Publication No. 95-3157. One Year Initiation/Promotion Study of o-Benzyl-p-chlorophenol (CAS NO. 120-32-1) in Swiss (CD-1) Mice (Mouse Skin Study). (accessed 25.04.13). http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr444.pdf.
69. NTP, 2004. NTP Technical Report on the Toxicology and Carcinogenesis Studies of Elmiron (Cas No. 37319-17-8) in F344/N Rats and B6C3F1 Mice (Gavage Studies). (accessed 25.04.13). http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr512.pdf.
70. NTP, 2011. 12th Report on Carcinogens (RoC). (accessed 25.04.13). http://ntp.niehs.nih.gov/go/roc12.
71. NTP, 2012. Historical Controls. Last updated on 15 November 2012. (accessed 25.04.13). http://ntp.niehs.nih.gov/go/14692.
72. NTP, 2013. (accessed 25.04.13). http://ntp-server.niehs.nih.gov/.
73. OECD, 2009. OECD Guideline for the Testing of Chemicals: Test No. 453: Combined Chronic Toxicity/Carcinogenicity Studies. (accessed 25.04.13). http://www.oecdbookshop.org/oecd/display.asp?lang=en&sf1=DI&st1=5LMQCR2K7MJG.
74. OEHHA, 2013. California Office of Environmental Health Hazard Assessment (OEHHA). Proposition 65 List of Chemicals. (accessed 25.04.13). http://oehha.ca.gov/prop65/prop65_list/Newlist.html.
75. Office of Science and Technology Policy/Executive Office of the President, 1985. Chemical Carcinogens; A Review of the Science and its Associated Principles. The Federal Register 15(50):10372-10442, March 14, 1985. (accessed 25.04.13). https://www.federalregister.gov/.
76. Olsen J.H., Boice J.D., Jensen J.P., Fraumeni J.F. Cancer among epileptic patients exposed to anticonvulsant drugs. J. Natl. Cancer Inst. 1989, 81:803-808.
77. Olsen J.H., Schulgen G., Boice J.D., Whysner J., Travis L.B., Williams G.M., Johnson F.B., McGee J.O. Antiepileptic treatment and risk for hepatobiliary cancer and malignant lymphoma. Cancer Res. 1995, 55:294-297.
78. Omenn G.S., Stuebbe S., Lave L.B. Predictions of rodent carcinogenicity testing results: interpretation in light of the Lave-Omenn value-of-information model. Mol. Carcinog. 1995, 14:37-45.
79. Parzefall W., Erber E., Sedivy R., Schulte-Hermann R. Testing for induction of DNA synthesis in human hepatocyte primary cultures by rat liver tumor promoters. Cancer Res. 1991, 51:1143-1147.
80. People for the Ethical Treatment of Animals (PETA), 2013. Animals Used for Experimentation. (accessed 15.04.13). http://www.peta.org/issues/animals-used-for-experimentation/default.aspx.
81. Pfuhler S., Kirkland D., Kasper P., Hayashi M., Vanparys P., Carmichael P., Dertinger S., Eastmond D., Elhajouji A., Krul C., Rothfuss A., Schoening G., Smith A., Speit G., Thomas C., van Benthem J., Corvi R. Reduction of use of animals in regulatory genotoxicity testing: Identification and implementation opportunities - report from an ECVAM workshop. Mutat. Res. 2009, 680:31-42.
82. PubMed, 2013. National Center for Biotechnology Information, U.S. National Library of Medicine. (accessed 25.04.13). http://www.ncbi.nlm.nih.gov/pubmed.
83. Reddy M.V., Sistare F.D., Christensen J.S., Deluca J.G., Wollenberg G.K., Degeorge J.J. An evaluation of chronic 6- and 12-month rat toxicology studies as predictors of 2-year tumor outcome. Vet. Pathol. 2010, 47:614-629.
84. Schach von Wittenau M., Estes P.C. The redundancy of mouse carcinogenicity bioassays. Fundam. Appl. Toxicol. 1983, 3:631-639.
85. Schulte-Hermann R., Bursch W., Parzefall W. Mitogenesis and programmed cell death as determinants of carcinogenicity of nongenotoxic compounds. Chemically Induced Cell Proliferation: Implications for Risk Assessment 1991, Wiley-Liss Inc., New York. 1991/01/01 ed. B.E. Butterworth, T.J. Slaga, W. Farland, M. McClain (Eds.).
86. Sistare F.D., Morton D., Alden C., Christensen J., Keller D., Jonghe S.D., Storer R.D., Reddy M.V., Kraynak A., Trela B., Bienvenu J.G., Bjurstrom S., Bosmans V., Brewster D., Colman K., Dominick M., Evans J., Hailey J.R., Kinter L., Liu M., Mahrt C., Marien D., Myer J., Perry R., Potenta D., Roth A., Sherratt P., Singer T., Slim R., Soper K., Fransson-Steen R., Stoltz J., Turner O., Turnquist S., van Heerden M., Woicke J., DeGeorge J.J. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines. Toxicol. Pathol. 2011, 39:716-744.
87. Sonich-Mullin C., Fielder R., Wiltse J., Baetcke K., Dempsey J., Fenner-Crisp P., Grant D., Hartley M., Knaap A., Kroese D., Mangelsdorf I., Meek E., Rice J.M., Younes M. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul. Toxicol. Pharmacol. 2001, 34:146-152.
88. Stouten H., Bessems J.G. Toxicological profile for o-benzyl-p-chlorophenol. J. Appl. Toxicol. 1998, 18:271-279.
89. United Nations, 2011. GHS Part 3 Health Hazards. (accessed 25.04.13). http://www.unece.org/fileadmin/DAM/trans/danger/publi/ghs/ghs_rev04/English/03e_part3.pdf.
90. USEPA, 1998. Health Effects Test Guidelines, OPPTS 870.4200. Carcinogenicity. (accessed 25.04.13). http://www.epa.gov/ocspp/pubs/frs/publications/Test_Guidelines/series870.htm.
91. USEPA, 2010. Evaluating Pesticides for Carcinogenic Potential. (accessed 25.04.13). http://www.epa.gov/opp00001/health/cancerfs.htm.
92. Van Oosterhout J.P., Van der Laan J.W., De Waal E.J., Olejniczak K., Hilgenfeld M., Schmidt V., Bass R. The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul. Toxicol. Pharmacol. 1997, 25:6-17.
93. Ward J.M. Lymphomas and leukemias in mice. Exp. Toxicol. Pathol. 2006, 57:377-381.
94. Whysner J., Ross P.M., Williams G.M. Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol. Ther. 1996, 71:153-191.
95. Williams G.M. Chemicals with carcinogenic activity in the rodent liver; mechanistic evaluation of human risk. Cancer Lett. 1997, 117:175-188.